Discovery of Novel PROTAC SIRT6 Degraders with Potent Efficacy against Hepatocellular Carcinoma

Jinbo Huang; Jiajie Su; Haiyu Wang; Jiayi Chen; Yuan Tian; Jun Zhang; Tingting Feng; Longjiang Di; Xiaopeng Lu; Hao Sheng; Qian Zhu; Xinyun Chen; J. Wang; Xingkai He; Yerkezhan Yerkinkazhina; Zhongyi Xie; Yuxin Shu; Tian‐Shu Kang; Huangqi Tang; Jinqin Qian; Wei‐Guo Zhu

doi:10.1021/acs.jmedchem.4c01223

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Sirtuin 6 (SIRT6), a member of the SIRT family, plays essential roles in the regulation of metabolism, inflammation, aging, DNA repair, and cancer development, making it a promising anticancer drug target. Herein, we present our use of proteolysis-targeting chimera (PROTAC) technology to formulate a series of highly potent and selective SIRT6 degraders. One of the degraders,

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Huang et al. (2024) studied this question.

synapsesocial.com/papers/68e57432b6db6435875144c1 https://doi.org/10.1021/acs.jmedchem.4c01223

View at Publisher

Ask AI

Bookmark

Share

Discovery of Novel PROTAC SIRT6 Degraders with Potent Efficacy against Hepatocellular Carcinoma

Ask about this paper

Abstract

Discussion

Cite This Study

Discovery of Novel PROTAC SIRT6 Degraders with Potent Efficacy against Hepatocellular Carcinoma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading